BR112018009714A8 - ligantes de tnf aperfeiçoados - Google Patents

ligantes de tnf aperfeiçoados

Info

Publication number
BR112018009714A8
BR112018009714A8 BR112018009714A BR112018009714A BR112018009714A8 BR 112018009714 A8 BR112018009714 A8 BR 112018009714A8 BR 112018009714 A BR112018009714 A BR 112018009714A BR 112018009714 A BR112018009714 A BR 112018009714A BR 112018009714 A8 BR112018009714 A8 BR 112018009714A8
Authority
BR
Brazil
Prior art keywords
tnf
polypeptides
bind
compounds
necrosis factor
Prior art date
Application number
BR112018009714A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112018009714A2 (en
Inventor
Van Heeke Gino
Boucneau Joachim
Buyse Marie-Ange
Casteels Peter
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of BR112018009714A2 publication Critical patent/BR112018009714A2/en
Publication of BR112018009714A8 publication Critical patent/BR112018009714A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Insulating Materials (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
BR112018009714A 2015-11-12 2016-11-14 ligantes de tnf aperfeiçoados BR112018009714A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562254375P 2015-11-12 2015-11-12
US62/254,375 2015-11-12
PCT/EP2016/077595 WO2017081320A1 (en) 2015-11-12 2016-11-14 Improved tnf binders

Publications (2)

Publication Number Publication Date
BR112018009714A2 BR112018009714A2 (en) 2018-11-21
BR112018009714A8 true BR112018009714A8 (pt) 2019-02-26

Family

ID=57348648

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009714A BR112018009714A8 (pt) 2015-11-12 2016-11-14 ligantes de tnf aperfeiçoados

Country Status (37)

Country Link
US (2) US10544211B2 (enExample)
EP (2) EP3191511B1 (enExample)
JP (2) JP6962915B2 (enExample)
KR (2) KR20240029115A (enExample)
CN (1) CN108473563B (enExample)
AU (2) AU2016352943B2 (enExample)
BR (1) BR112018009714A8 (enExample)
CA (2) CA3234178A1 (enExample)
CL (1) CL2018001291A1 (enExample)
CO (1) CO2018005915A2 (enExample)
CR (1) CR20180311A (enExample)
CY (1) CY1120303T1 (enExample)
DK (1) DK3191511T3 (enExample)
DO (1) DOP2018000122A (enExample)
EC (1) ECSP18042569A (enExample)
ES (1) ES2662418T3 (enExample)
GT (1) GT201800095A (enExample)
HK (1) HK1248716A1 (enExample)
HR (1) HRP20171949T1 (enExample)
HU (1) HUE035805T2 (enExample)
IL (2) IL310373A (enExample)
LT (1) LT3191511T (enExample)
MA (1) MA41653A (enExample)
MD (1) MD3191511T2 (enExample)
ME (1) ME02954B (enExample)
MX (1) MX385207B (enExample)
NO (1) NO2768984T3 (enExample)
PE (1) PE20181317A1 (enExample)
PH (1) PH12018501025A1 (enExample)
PL (1) PL3191511T3 (enExample)
PT (1) PT3191511T (enExample)
RS (1) RS56676B1 (enExample)
SG (1) SG11201803975SA (enExample)
SI (1) SI3191511T1 (enExample)
SM (1) SMT201700590T1 (enExample)
TN (1) TN2018000159A1 (enExample)
WO (1) WO2017081320A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PL2723769T5 (pl) 2011-06-23 2022-10-17 Ablynx Nv Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
SG10201810124PA (en) 2014-05-16 2018-12-28 Ablynx Nv Improved immunoglobulin variable domains
NO2768984T3 (enExample) * 2015-11-12 2018-06-09
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2021110816A1 (en) 2019-12-06 2021-06-10 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23
CN114980923A (zh) * 2019-12-06 2022-08-30 艾伯霖克斯公司 包含靶向TNFα和OX40L的免疫球蛋白单可变结构域的多肽
CN112300289B (zh) * 2019-12-30 2022-06-10 中国药科大学 RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
EP4435002A4 (en) * 2021-11-29 2025-03-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. MODIFIED PROTEIN OR POLYPEPTIDE
AU2023373192A1 (en) * 2022-11-04 2025-04-17 St. Jude Children's Research Hospital, Inc. Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
CN120712282A (zh) 2023-02-17 2025-09-26 阿布林克斯有限公司 结合新生儿fc受体的多肽

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
KR20010034512A (ko) 1998-02-19 2001-04-25 베렌슨, 론 림프구 활성화 조절을 위한 조성물 및 그 방법
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
EP2251357A1 (en) 2003-11-07 2010-11-17 Ablynx N.V. Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
KR20070086896A (ko) 2004-12-02 2007-08-27 도만티스 리미티드 항­ｉｌ­1ｒ1 단일 도메인 항체 및 치료적 용도
CN103254309B (zh) * 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
PL2444424T3 (pl) 2005-05-20 2019-01-31 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
EP1948206B1 (en) 2005-08-30 2017-03-01 Intrexon Actobiotics NV Anti-tnf alpha producing lactic acid bacteria for the treatment of inflammatory bowel disease
AU2006321364B2 (en) 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
CA2629850A1 (en) 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
AU2007209201A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
NZ581097A (en) 2007-05-24 2012-03-30 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
CA2706200A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs comprising multiple single variable domains and an fc portion
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
MX2010012518A (es) 2008-05-16 2010-12-06 Ablynx Nv Secuencias de aminoacidos dirigidas contra cxcr4 y otros receptores acoplados a proteina g y compuestos que comprenden los mismos.
BRPI1008014A2 (pt) * 2009-02-19 2016-10-04 Glaxo Group Ltd domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro
KR20130119990A (ko) 2009-04-10 2013-11-01 아블린쓰 엔.브이. Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
MX2012000765A (es) 2009-07-16 2012-02-13 Glaxo Group Ltd Dominios variables sencillos de union de albumina anti-suero mejorados.
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
EP4218933A1 (en) 2011-06-23 2023-08-02 Ablynx NV Serum albumin binding proteins
PL2723769T5 (pl) * 2011-06-23 2022-10-17 Ablynx Nv Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny
MY167125A (en) * 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
SG10201810124PA (en) * 2014-05-16 2018-12-28 Ablynx Nv Improved immunoglobulin variable domains
NO2768984T3 (enExample) 2015-11-12 2018-06-09
EP3414268A1 (en) * 2016-02-12 2018-12-19 Ablynx NV Method for the production of immunoglobulin single variable domains

Also Published As

Publication number Publication date
CA3005085A1 (en) 2017-05-18
CL2018001291A1 (es) 2018-09-14
PH12018501025A1 (en) 2019-01-28
CN108473563A (zh) 2018-08-31
CY1120303T1 (el) 2019-07-10
DK3191511T3 (en) 2018-01-08
PE20181317A1 (es) 2018-08-14
RS56676B1 (sr) 2018-03-30
EP3266798A3 (en) 2018-03-28
EP3191511B1 (en) 2017-09-20
JP6962915B2 (ja) 2021-11-10
KR102641194B1 (ko) 2024-02-26
ES2662418T3 (es) 2018-04-06
LT3191511T (lt) 2018-01-10
IL310373A (en) 2024-03-01
JP2022020666A (ja) 2022-02-01
NO2768984T3 (enExample) 2018-06-09
ECSP18042569A (es) 2018-07-31
EP3266798A2 (en) 2018-01-10
IL259269B2 (en) 2024-07-01
US9745372B2 (en) 2017-08-29
EP3191511A1 (en) 2017-07-19
HUE035805T2 (en) 2018-05-28
ME02954B (me) 2018-07-20
IL259269A (en) 2018-07-31
PT3191511T (pt) 2017-11-30
US20170267752A1 (en) 2017-09-21
GT201800095A (es) 2019-08-15
CN108473563B (zh) 2022-06-14
JP7357038B2 (ja) 2023-10-05
HRP20171949T1 (hr) 2018-01-26
WO2017081320A1 (en) 2017-05-18
DOP2018000122A (es) 2018-09-30
JP2019506839A (ja) 2019-03-14
US10544211B2 (en) 2020-01-28
RU2018120524A (ru) 2019-12-13
AU2023200113A1 (en) 2023-02-16
MA41653A (fr) 2018-01-09
HK1248716A1 (en) 2018-10-19
SG11201803975SA (en) 2018-06-28
AU2016352943B2 (en) 2022-10-20
KR20240029115A (ko) 2024-03-05
MX385207B (es) 2025-03-04
CO2018005915A2 (es) 2018-06-20
KR20180083382A (ko) 2018-07-20
BR112018009714A2 (en) 2018-11-21
AU2016352943A1 (en) 2018-06-07
US20170190769A1 (en) 2017-07-06
CA3234178A1 (en) 2017-05-18
SI3191511T1 (en) 2018-01-31
MX2018005992A (es) 2019-01-31
IL259269B1 (en) 2024-03-01
RU2018120524A3 (enExample) 2020-09-24
MD3191511T2 (ro) 2018-03-31
CR20180311A (es) 2018-10-18
SMT201700590T1 (it) 2018-01-11
PL3191511T3 (pl) 2018-03-30
CA3005085C (en) 2024-09-10
TN2018000159A1 (en) 2019-10-04

Similar Documents

Publication Publication Date Title
BR112018009714A8 (pt) ligantes de tnf aperfeiçoados
MX2023003630A (es) Aglutinantes de albumina de suero mejorados.
MX2023005374A (es) Aglutinantes de albumina serica mejorados.
MX2025010630A (es) Aglutinantes de albumina serica mejorados
BR112018070998A2 (pt) proteínas de ligação triespecíficas e/ou trivalentes
DOP2019000011A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
WO2017085172A3 (en) Improved serum albumin binders
MY200335A (en) Bispecific binding proteins and uses thereof
MX373485B (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
HRP20220531T1 (hr) Varijabilni fragmenti antitijela koji se umeću i modificirane a1-a2 domene nkg2d liganda
EA201791057A1 (ru) Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
EA201400811A1 (ru) Двойная индуцированная антигеном двухкомпонентная функциональная комплементация
EA201790438A1 (ru) Антигенсвязывающие белки, которые связываются с cxcr5
EA201691589A1 (ru) Стабилизированные основанные на фибронектине каркасные молекулы
BR112016024462A2 (pt) ?métodos para a preparação de uma proteína, proteína heteromultimérica, composição e célula hospedeira?

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]